home / stock / cntb / cntb quote
Last: | $1.33 |
---|---|
Change Percent: | -0.75% |
Open: | $1.35 |
Close: | $1.33 |
High: | $1.41 |
Low: | $1.28 |
Volume: | 43,786 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.33 | $1.35 | $1.33 | $1.41 | $1.28 | 43,786 | 07-05-2024 |
$1.34 | $1.36 | $1.34 | $1.39 | $1.3 | 27,638 | 07-04-2024 |
$1.34 | $1.36 | $1.34 | $1.39 | $1.3 | 27,638 | 07-03-2024 |
$1.38 | $1.55 | $1.38 | $1.55 | $1.35 | 18,861 | 07-02-2024 |
$1.44 | $1.63 | $1.44 | $1.63 | $1.4084 | 27,978 | 07-01-2024 |
$1.52 | $1.28 | $1.52 | $1.73 | $1.25 | 842,159 | 06-28-2024 |
$1.28 | $1.36 | $1.28 | $1.36 | $1.28 | 208,466 | 06-27-2024 |
$1.33 | $1.36 | $1.33 | $1.36 | $1.3 | 30,700 | 06-26-2024 |
$1.33 | $1.435 | $1.33 | $1.528 | $1.33 | 38,824 | 06-25-2024 |
$1.35 | $1.46 | $1.35 | $1.46 | $1.35 | 36,050 | 06-24-2024 |
$1.39 | $1.39 | $1.39 | $1.56 | $1.35 | 58,752 | 06-21-2024 |
$1.4472 | $1.48 | $1.4472 | $1.6 | $1.44 | 56,552 | 06-20-2024 |
$1.49 | $1.61 | $1.49 | $1.69 | $1.42 | 105,665 | 06-19-2024 |
$1.49 | $1.61 | $1.49 | $1.69 | $1.42 | 105,665 | 06-18-2024 |
$1.65 | $1.6 | $1.65 | $1.73 | $1.6 | 31,532 | 06-17-2024 |
$1.6 | $1.79 | $1.6 | $1.79 | $1.53 | 26,214 | 06-14-2024 |
$1.68 | $1.76 | $1.68 | $1.76 | $1.6 | 39,984 | 06-13-2024 |
$1.77 | $1.95 | $1.77 | $1.95 | $1.7001 | 31,893 | 06-12-2024 |
$1.83 | $2.02 | $1.83 | $2.02 | $1.8 | 185,392 | 06-11-2024 |
$2.04 | $1.92 | $2.04 | $2.0699 | $1.79 | 67,893 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Connect Biopharma Holdings Limited Company Name:
CNTB Stock Symbol:
NASDAQ Market:
Connect Biopharma Holdings Limited Website:
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases thr...
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases thr...
Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24 Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24 End of Phase 2 (EoP2) meeting i...